GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Hong Kong · Delayed Price · Currency is HKD

38.36

+2.36 (6.56%)

Jul 10, 2026, 4:08 PM HKT

-12.82% (1Y)

Market Cap	14.21B
Revenue (ttm)	144.96M +24.4%
Net Income	-2.00B
EPS	-6.75
Shares Out	370.37M
PE Ratio	n/a
Forward PE	9.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,060,365
Open	35.98
Previous Close	36.00
Day's Range	35.00 - 40.82
52-Week Range	19.60 - 52.90
Beta	n/a
Analysts	Strong Buy
Price Target	51.01 (+32.98%)
Earnings Date	Mar 24, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibit... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country China

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2595

Full Company Profile

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 2595 stock is "Strong Buy." The 12-month stock price target is $51.01, which is an increase of 32.98% from the latest price.

Price Target

$51.01

(32.98% upside)

Analyst Consensus: Strong Buy

Stock Forecasts